Jafron Biomedical Co.,Ltd. (SHE: 300529)

Market Cap	18.91B
Revenue (ttm)	2.41B
Net Income (ttm)	711.49M
Shares Out	774.36M
EPS (ttm)	0.89
PE Ratio	27.37
Forward PE	21.05
Dividend	0.40 (1.64%)
Ex-Dividend Date	May 31, 2024

Volume	2,969,000
Open	25.43
Previous Close	24.42
Day's Range	24.28 - 25.43
52-Week Range	15.88 - 30.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Jafron Biomedical Co.,Ltd.

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,408
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2023, Jafron Biomedical Co.,Ltd.'s revenue was 1.92 billion, a decrease of -22.84% compared to the previous year's 2.49 billion. Earnings were 436.49 million, a decrease of -50.93%.